Articul8 launches Bivia to bring domain-specific decision intelligence to enterprise AI agents Agra Ventures’ Boundary Bay Cannabis JV Receives Over $910,000 in Purchase Orders in Last 3 Months
While Boundary Bay Cannabis Received Demand for Over 725,000 Grams of High-Quality Bulk Cannabis in…
Agra Ventures’ Boundary Bay Cannabis JV Receives Over $910,000 in Purchase Orders in Last 3 Months
While Boundary Bay Cannabis Received Demand for Over 725,000 Grams of High-Quality Bulk Cannabis in…
Aclaris Therapeutics and Pediatrix Therapeutics Announce License Agreement for ATI-1777 in Greater China
WAYNE, Pa. and SHANGHAI, China, Nov. 29, 2022 (GLOBE NEWSWIRE) — Aclaris Therapeutics, Inc. (NASDAQ:…
Aclaris Therapeutics and Pediatrix Therapeutics Announce License Agreement for ATI-1777 in Greater China
WAYNE, Pa. and SHANGHAI, China, Nov. 29, 2022 (GLOBE NEWSWIRE) — Aclaris Therapeutics, Inc. (NASDAQ:…
Atea Pharmaceuticals Announces First Patient Dosed in SUNRISE-3 Phase 3 Registrational Trial of Bemnifosbuvir, an Investigational Oral Antiviral for the Treatment of COVID-19
Global Study to Evaluate Bemnifosbuvir as Monotherapy and in Combination in Non-Hospitalized Patients at High…
Atea Pharmaceuticals Announces First Patient Dosed in SUNRISE-3 Phase 3 Registrational Trial of Bemnifosbuvir, an Investigational Oral Antiviral for the Treatment of COVID-19
Global Study to Evaluate Bemnifosbuvir as Monotherapy and in Combination in Non-Hospitalized Patients at High…
ALX Oncology Appoints Scott Garland to its Board of Directors
SOUTH SAN FRANCISCO, Calif., Nov. 29, 2022 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc., (“ALX…
ALX Oncology Appoints Scott Garland to its Board of Directors
SOUTH SAN FRANCISCO, Calif., Nov. 29, 2022 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc., (“ALX…
Trevena Regains Compliance with Nasdaq Listing Requirements
CHESTERBROOK, Pa., Nov. 29, 2022 (GLOBE NEWSWIRE) — Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company…
Trevena Regains Compliance with Nasdaq Listing Requirements
CHESTERBROOK, Pa., Nov. 29, 2022 (GLOBE NEWSWIRE) — Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company…
Femasys Inc. Announces Enrollment is over 25% Complete for FemaSeed® De Novo Trial Following Updated Strategic Study Design
–FemaSeed de novo trial enrollment has accelerated with trial recruitment focus on male factor infertility–…
Femasys Inc. Announces Enrollment is over 25% Complete for FemaSeed® De Novo Trial Following Updated Strategic Study Design
–FemaSeed de novo trial enrollment has accelerated with trial recruitment focus on male factor infertility–…
BiondVax reports successful results in preclinical in vivo study of its innovative inhaled COVID-19 NanoAb therapy
Hamsters infected with SARS-COV-2 and then treated with inhaled anti-COVID-19 NanoAbs demonstrated significantly less severe…
BiondVax reports successful results in preclinical in vivo study of its innovative inhaled COVID-19 NanoAb therapy
Hamsters infected with SARS-COV-2 and then treated with inhaled anti-COVID-19 NanoAbs demonstrated significantly less severe…
PolyPid Announces Presentation of Phase 2 D-PLEX₁₀₀ Clinical Data at the First Triennial Meeting of the International Orthopaedic Trauma Association
D-PLEX₁₀₀ Infection Prevention Efficacy in Patients with Increased Risk for Surgical Wound Infections Including Multi-Drug…
PolyPid Announces Presentation of Phase 2 D-PLEX₁₀₀ Clinical Data at the First Triennial Meeting of the International Orthopaedic Trauma Association
D-PLEX₁₀₀ Infection Prevention Efficacy in Patients with Increased Risk for Surgical Wound Infections Including Multi-Drug…
atai Life Sciences Strengthens Leadership Team with Appointment of Dr. Sahil V. Kirpekar as Chief Business Officer
– Dr. Kirpekar joins from Otsuka Pharmaceutical where he was Head of Business Development and…
atai Life Sciences Strengthens Leadership Team with Appointment of Dr. Sahil V. Kirpekar as Chief Business Officer
– Dr. Kirpekar joins from Otsuka Pharmaceutical where he was Head of Business Development and…
Kineta to Participate in JMP Securities Hematology and Oncology Summit
SEATTLE, Nov. 29, 2022 (GLOBE NEWSWIRE) — Kineta, Inc. (“Kineta” or the “Company”), a clinical-stage…
Kineta to Participate in JMP Securities Hematology and Oncology Summit
SEATTLE, Nov. 29, 2022 (GLOBE NEWSWIRE) — Kineta, Inc. (“Kineta” or the “Company”), a clinical-stage…